3Amagai M. Autoimmune and infectious skin diseases that target desmogleins[J]. Proc Jpn Acad Ser B Phys Biol Sci, 2010, 86 (5): 524-537.
4Ishii K, Harada R, Matsuo I,et al. In Vitro Keratinocyte Disso- ciation Assay for Evaluation of the Pathogenicity of Anti- Desmoglein 3 IgG Autoantibodies in Pemphigus Vulgaris [J]. J Invest Dermatol, 2005, 124: 939-946.
5朱学骏,涂平.皮肤病的组织病理诊断[M].北京:北京大学医学出版社.2009:141.
6Manges AR, Perdreau RF, Solberg O, et al. Muhidrug-resistant Escherichia coli clonal groups causing community-acquired bloodstream infections[J]. J Infect, 2006, 53: 25-29.
7Giircan HM, Jeph S, Ahmed AR. Intravenous immunoglohulin therapy in autoimmune mucocutaneous blistering diseases: a re- view of the evidence for its efficacy and safety [J]. Am J Clin Dermatol, 2010, 11(5): 315-326.
8Fernandes NC, Perez M. Treatment of pemphigus vulgaris and pemphigus foliaceus: experience with 71 patient over a 20 year period [J]. Rev Inst Med Trop Sao Paulo, 2001, 43(1): 33-36.
9Donald E. Morisky,Lawrence W. Green,David M. Levine.Concurrent and Predictive Validity of a Self-reported Measure of Medication Adherence[J].Medical Care.1986(1)
